The dual nature of TGF-β inhibition has been highlighted through gene therapy to elevate soluble TβRII or the use of neutralizing TGF-β antibodies in mice, also emphasizing the critical role of timing in the context of myocardial infarction. Here, TGFB1 is linked to myocardial infarction.